Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 5

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 5
---
imeric antigen receptors are receptor proteins that have been engineered to give T cells the new ability to target a specific antigen.

Small molecule: We have identified and patented a series of small molecules which can both activate and inhibit NR2F6. We are currently in pre-clinical testing of these drugs.

None of the abovementioned statements regarding any of our products in development are intended to be a prediction or conclusion of efficacy. No clinical trials on our product candidates have commenced so no conclusions of efficacy can be made.

As of August 13, 2025 we have not licensed any existing therapies which may be marketed.

The Company has entered into license agreements with Zander Therapeutics, Inc. ( an entity under common control) and Oncology Pharma Inc. ( an unrelated entity).

Both Zander and Oncology Pharma, Inc. will be required to obtain approval from the United States Food and Drug Administration (“FDA”) in order to market any Licensed Product which may be developed within the United States and no assurance may be given that such approval would be granted.

| 5 |

Selected Financial Data

The stockholders’ equity section of the Company contains the following classes of capital stock :

As of August 21 , 2025

Common stock, $ 0.0001 par value; 5, 800,000,000 shares authorized: 33,554,704 shares issued and outstanding.

Preferred Stock, $0.0001 par value, 800,000,000 shares authorized of which 600,000 is designated as Series AA Preferred Stock: 34 shares issued and outstanding as of August 13, 2025, 540,000,000 is designated Series A Preferred Stock of which 10,123,771 shares are outstanding as of August 13, 2025, 60,000,000 is designated Series M Preferred Stock of which 29,338 shares are outstanding as of August 13, 2025 and 20,000 is designated Series NC Preferred Stock of which 15,007 shares are outstanding as of August 13, 2025.

Our common stock is traded on the OTCID under the symbol “RGBP” and our Series A Preferred stock is traded on the OTCID under the symbol “RGBPP”. No public market currently exists for any other equity securities of the Company.

|                                      |     | At June 30, 2025 
 (unaudited)      |            |   |
|:-------------------------------------|:----|:-----------------